Biodesix, Inc.

    Jurisdiction
    United States
    ISIN
    US09075X1081 (BDSX)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €65.72M
    Gross margin
    78.8%
    EBIT
    -€29.27M
    EBIT margin
    -44.5%
    Net income
    -€35.26M
    Net margin
    -53.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €89.90M +36.8% -€25.55M -27.6%
    €109.41M +21.7% -€18.75M -26.6%
    €120.62M +10.3% -€9.42M -49.8%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    SCHULER JACK W N/A +3.5M $0.43 +$1.50M
    Cowie Robin Harper CFO, Sec'y & Treasurer -988 $0.42 -$414.96
    Hutton Scott President & CEO -3.8K $0.42 -$1.58K
    O'Kane Kieran Chief Commercial Officer -476 $0.42 -$199.92
    Pestano Gary Anthony Chief Development Officer -442 $0.42 -$185.64

    Earnings Calls

    Latest earnings call: May 10, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 371K $231.76K +525 Buy

    Add to watchlist

    Notifications